Duloxetine
ApprovedUNKNOWN 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Major Depression
Conditions
Major Depression
Trial Timeline
Jul 1, 2011 โ Aug 1, 2013
NCT ID
NCT01391221About Duloxetine
Duloxetine is a approved stage product being developed by Eli Lilly for Major Depression. The current trial status is unknown. This product is registered under clinical trial identifier NCT01391221. Target conditions include Major Depression.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391221 | Approved | UNKNOWN |
| NCT01363284 | Pre-clinical | Completed |
| NCT01089621 | Approved | Withdrawn |
| NCT01051466 | Approved | Completed |
| NCT00989157 | Phase 3 | Completed |
| NCT01074151 | Pre-clinical | Completed |
| NCT00889369 | Approved | UNKNOWN |
| NCT01754493 | Approved | Completed |
| NCT01028352 | Pre-clinical | Completed |
| NCT00696774 | Approved | Completed |
| NCT00532480 | Approved | Completed |
| NCT00529789 | Phase 2 | Completed |
| NCT00696293 | Approved | Completed |
| NCT00517985 | Approved | Completed |
| NCT00398632 | Approved | Terminated |
| NCT00401258 | Approved | Completed |
| NCT00438971 | Approved | Completed |
| NCT00531895 | Approved | Completed |
| NCT00322621 | Approved | Completed |
| NCT01035073 | Approved | Completed |
Competing Products
20 competing products in Major Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 33 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 85 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 52 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 33 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 33 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 77 |